News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation

AR-13324-CS205 Clinical Pilot Study Topline Results

Press Release: AR-13324-CS205 Clinical Pilot Study Topline Results

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant)
Phase 2 Clinical Study Initiating Later in First Quarter 2019 DURHAM, N.C. --(BUSINESS WIRE)--Jan. 17, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan
Announces Opening of Tokyo Branch Office and Two Key Hires in Japan DURHAM, N.C. --(BUSINESS WIRE)--Jan. 4, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access
DURHAM, N.C. --(BUSINESS WIRE)--Jan. 2, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 7, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML